PPIB and neuroblastoma: In 2013 twenty-four patients with chemo-resistant NB were enrolled to receive 10 mg/(kg·day) of 3F8 (a mAb directed against the ganglioside GD2, a NB surface antigen) associated in each cycle to an oral β-glucan, dose escalated from 10 to 80 mg/(kg·day).